Core Viewpoint - The article discusses the rising interest and regulatory challenges surrounding exosomes, a substance claimed to have anti-aging effects, which has not yet received approval for medical use in China [3][5]. Group 1: Regulatory Environment - The National Medical Products Administration in China has issued a draft for public consultation regarding the regulation of exosomes, which are still in the research phase and have not been approved for sale [3][5]. - There are concerns about the illegal use of exosomes in products, with some companies using improper certifications to market these substances, violating medical device regulations [5][6]. Group 2: Market Dynamics - Despite the lack of approved exosome products, companies like New Oxygen have previously launched related aesthetic medical products, although they have since been taken down [5]. - The consumer medical market is booming, prompting some CDMO manufacturers, originally focused on cell and gene therapy, to explore exosome-related businesses [6][7]. Group 3: Safety and Clinical Research - Experts warn about the safety of using exosomes in humans without proper regulatory approval, emphasizing the need for rigorous preclinical and clinical studies to validate safety and efficacy [7][8]. - Approximately 300 clinical trials related to exosomes are currently underway in China, with over 70 new studies registered in the past year, targeting various conditions such as sensitive skin diseases, arthritis, and hair loss [7].

证券代码：688238 证券简称：和元生物 公告编号：2026-007 上海和元生物技术（集团）股份有限公司 关于公司名称变更完成工商登记并换发营业执照的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，公司已完成上述事项的工商变更登记及备案手续，并取得了由上海市 市场监督管理局换发的《营业执照》，变更后的相关工商登记信息如下： 1、名称：上海和元生物技术（集团）股份有限公司 2、统一社会信用代码：913100000625940784 5、成立日期：2013 年 3 月 5 日 1 6、法定代表人：潘讴东 上海和元生物技术（集团）股份有限公司（以下简称"公司"，原公司名称 为"和元生物技术（上海）股份有限公司"）分别于 2026 年 2 月 4 日、2026 年 2 月 26 日召开了第四届董事会第六次会议、2026 年第一次临时股东会，审议通过 了《关于变更公司名称、修订<公司章程>并办理工商变更登记的议案》，同意公 司中文名称变更为"上海和元生物技术（集团）股份有限公司"，英文名称变更 为"Shanghai ...

证券代码：688238 证券简称：和元生物 公告编号：2026-008 上海和元生物技术（集团）股份有限公司 关于参与设立产业投资基金进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称 上海金浦慕和私募投资基金合伙企业（有限 合伙） 投资金额（万元） 5,400 投资进展阶段 完成 终止 交易要素变更 进展 特别风险提示（如有请勾选） 募集失败 未能完成备案登记 提前终止 发生重大变更 其他： 根据《上海金浦慕和私募投资基金合伙企业（有限合伙）合伙人会议决议》 相关条款约定，经金浦慕和基金全体合伙人协商一致，同意基金认缴出资规模由 32,830 万元减少到 19,698 万元，全体合伙人按照同比例减少认缴出资额，并按 照其认缴出资额调整管理费。普通合伙人、基金管理人上海金浦新朋投资有限公 司更名为"上海金浦新朋私募基金管理有限公司"。公司前期已对基金实缴出资 人民币 5,400 万元，后续将不再继续出资。近日，公司收到基金管理人的通知， 金浦慕和基金已就前述减资事项完成工商变更登记手续 ...

Core Viewpoint - The company reported a significant reduction in net losses for the fiscal year 2025, indicating improved operational efficiency and revenue growth across its main business segments [1] Financial Performance - The total operating revenue for the company reached 268 million yuan, representing a year-on-year increase of 7.86% [1] - The net loss attributable to the parent company was 221 million yuan, which is an improvement compared to a loss of 322 million yuan in the same period last year [1] Operational Insights - All main business segments of the company achieved varying degrees of revenue growth during the reporting period [1] - The company increased its investment in research and development and focused on the application of technology, particularly through AI+ technology, to enhance R&D efficiency [1] - Operational costs and period expenses decreased compared to the same period last year due to these improvements [1] Cost Structure - Despite the improvements, the company still faced high fixed operational costs due to the large scale of asset operations at the Lingang base, including depreciation, energy consumption, and daily maintenance [1] - Overall profit remains negative, but the extent of the losses has significantly narrowed [1]

Group 1 - The company held its first extraordinary general meeting of shareholders on February 26, 2026, in Shanghai, with all board members present and the meeting conducted in accordance with legal regulations [2][3][4] - Two resolutions were passed during the meeting: one regarding the establishment of an industrial merger fund and related transactions, and another concerning the change of the company's name and amendments to the articles of association [4][5] - The resolutions received the necessary majority votes, with the second resolution requiring a two-thirds majority and the first resolution requiring a simple majority [5][6] Group 2 - The company reported its preliminary financial data for the year 2025, indicating a revenue of 267.66 million yuan, a year-on-year increase of 7.86%, and a net loss attributable to shareholders of 220.72 million yuan, a reduction in loss by 10.11 million yuan compared to the previous year [9][12] - The total assets at the end of the reporting period were 2.10 billion yuan, a decrease of 7.89%, while the equity attributable to shareholders decreased by 18.24% to 1.42 billion yuan [12][13] - The company focused on its core business in cell and gene therapy, leveraging national and industry development policies to strategically position itself in the regenerative medicine sector, while also enhancing customer resource reserves and brand influence [12][13]

Core Insights - The company, He Yuan Biotechnology, reported a revenue of 268 million yuan for 2025, representing a year-on-year growth of 7.86%, while the net loss decreased by 101 million yuan to 221 million yuan, indicating a significant recovery in operational fundamentals during the industry adjustment period [2] Group 1: Financial Performance - The company achieved a revenue of 268 million yuan in 2025, marking a 7.86% increase compared to the previous year [2] - The net loss for the year was 221 million yuan, which is a reduction of 101 million yuan from the previous year's loss [2] Group 2: Business Strategy and Operations - He Yuan Biotechnology has developed two core technology clusters in cell and gene therapy, focusing on carrier development, production processes, and quality control, forming a complete industrial chain layout with three main business divisions: CRO, CDMO, and regenerative medicine [2] - The company has served over 600 CDMO projects and assisted clients in obtaining more than 60 IND approvals domestically and internationally, showcasing its strong technical capabilities and industry experience [2] Group 3: Market Expansion and Cost Management - In response to the complex industry environment in 2025, the company actively expanded its market presence and achieved revenue growth across various business segments [3] - The company increased its R&D investment and focused on technology application transformation, utilizing AI technology to enhance R&D efficiency and promote digital transformation, which led to a reduction in operational costs and period expenses compared to the previous year [3] - The company announced plans to establish an industrial merger and acquisition fund, focusing on investments in the cell and gene therapy industry chain and related upstream and downstream sectors [3]

Core Viewpoint - The company reported a revenue of 268 million yuan for the fiscal year 2025, reflecting a year-on-year growth of 7.86%, but also recorded a net loss attributable to shareholders of 221 million yuan [1] Group 1: Financial Performance - The company achieved an operating revenue of 268 million yuan, which is a 7.86% increase compared to the same period last year [1] - The net loss attributable to the parent company's shareholders was 221 million yuan during the reporting period [1] Group 2: Industry Context - The domestic biopharmaceutical sector is characterized by both opportunities and challenges, showcasing a complex landscape of diversified development and intense market competition [1] - The company remains focused on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field [1] Group 3: Operational Strategy - The company emphasized strengthening customer resource reserves, enhancing brand influence, and promoting industry development during the reporting period [1] - The main performance goals include improving internal capabilities, upgrading operational management, and driving cost reduction and efficiency enhancement to lay a solid foundation for future business development [1]

Group 1 - The company reported a total operating revenue of 2,676.634 million yuan for the year 2025, representing a year-on-year growth of 7.86% [2] - The net profit attributable to the owners of the parent company was -2,207.157 million yuan for the same period [2]

Core Viewpoint - He Yuan Bio (688238.SH) reported a mixed performance for the fiscal year 2025, with revenue growth but continued net losses [1] Financial Performance - The company achieved operating revenue of 267.66 million yuan, representing a year-on-year increase of 7.86% [1] - The net profit attributable to the parent company was a loss of 220.72 million yuan, which is a reduction in losses by 101.10 million yuan compared to the previous year [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was a loss of 232.02 million yuan, reflecting a decrease in losses by 103.89 million yuan year-on-year [1] Industry Context - The domestic biopharmaceutical sector is characterized by both opportunities and challenges, showcasing a complex landscape of diversified development and intense market competition [1] - The company remains focused on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field [1] Operational Strategy - During the reporting period, the company emphasized strengthening customer resource reserves, enhancing brand influence, and promoting industry development [1] - The main performance goals included improving internal capabilities, upgrading operational management, and driving cost reduction and efficiency enhancement [1] - These efforts aim to gradually improve management quality and operational efficiency, laying a solid foundation for future business development [1]

An Road Shanghai 200002 P.R. China 中国上海市延安东路 222 号外滩中心 40 楼 20 Tel/电话:(8621) 6249 6040 Fax/传真:(8621) 6249 5611 Website/网址: www.jinmao.com.cn 上海市金茂律师事务所 关于和元生物技术(上海)股份有限公司 2026年第一次临时股东会之法律意见书 .lin Mao Law Firm H 致:和元生物技术(上海)股份有限公司 和元生物技术（上海）股份有限公司（以下简称"公司"）2026 年第一次临时 股东会〈以下简称"本次股东会"）于 2026年２月 26 日下午在公司会议室召开。 上海市金茂律师事务所（以下简称"本所"）经公司聘请并接受公司委托,委派茅 丽婧律师、赵可沁律师(以下简称"本所律师")出席本次股东会,并根据《中华 人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以 下简称"《证券法》")、中国证券监督管理委员会公布的《上市公司股东会规则》 (以下简称"《股东会规则》")等相关法律、法规和规范性文件以及《和元生物 技术(上海)股份有限公司章程》 ...